AlphAIAlphAI — Financial news for AI agents
Financial news API & MCP server

Financial newsfor AI agents.

Stock market news and SEC filing updates, scored for relevance and sentiment. Available through a REST API and MCP server.

Connect an agentRead the feed
Get a free API keyInsider trading tracker

Free tier available. No credit card.

10,000+
Articles scanned daily

Crawled and deduplicated across the open web.

6,900+
Sources monitored

Distinct publisher domains scanned in the last 30 days.

<1 in 5
Makes the feed

Only the best clear the relevance floor.

~6 min
SEC filing to feed

Median from EDGAR publication to an enriched, ticker-tagged row.

Top stories

All stories →
OtherOCT 259 / 10

Genmab reports Phase 3 trial shows major survival gains for ovarian cancer drug Rina‑S

Genmab A/S announced that its investigational antibody‑drug conjugate rinatabart sesutecan (Rina‑S) met its primary endpoint of progression‑free survival and the key secondary endpoint of overall survival in a global Phase 3 trial of platinum‑resistant ovarian cancer. In the intent‑to‑treat population of 584 patients, the drug cut the risk of disease progression or death by 71% and reduced the risk of death by 57% versus investigator‑chosen chemotherapy. The company said the safety profile was consistent with earlier data and will discuss the results with regulators worldwide.

$GMAB10 sources · 7 publishers
Delivery

News alerts in Telegram, email, or a webhook.

Set up alerts →
On the wire
$BNTXBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy$LLYResponses to Lilly's experimental lung cancer combo lasted a median 14.5 months$MSFTWashington bans Chinese AI model DeepSeek, Microsoft abandons major UK project: The week’s key developments

Latest

See all news →
OCT 25
$XNCRMedAI 8/10

A cancer drug shrank tumors in 5 of 11 patients; 82% were estimated to be alive without worsening cancer at six months.

Xencor presented Phase 1 data for XmAb819, showing tumor shrinkage in 5 of 11 advanced ccRCC patients. The company plans FDA discussions for accelerated approval in 2027. XmAb819 demonstrated a 45% confirmed objective response rate in heavily pre-treated patients. Xencor will host a webcast to discuss the results and development plans.

stocktitan.net2 min
OCT 25
$AMGNLow

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?

Amgen (AMGN) and Gilead Sciences (GILD) are biotech stocks offering dividends. Amgen has a higher yield (2.2%) and stronger product sales growth (9% YoY), while Gilead has a lower payout ratio (43.5%) and trades at a lower valuation (15.6x forward earnings). Amgen's pipeline has 29 late-stage programs, while Gilead's has 53 clinical-stage programs, with 15 in Phase 3.

fool.com2 min
OCT 25
$CMGLow

“Not Buying”: Chipotle Just Dropped 16% in a Month. Is It Time to Sell, or Load Up?

Chipotle (CMG) stock fell 16% in a month, closing at $27.52 on October 23. Starbucks takeover speculation briefly boosted shares, but the company denied any plans. Chipotle's Q2 margins declined, and analysts lowered price targets ahead of October 28 earnings. The stock trades at a lower earnings multiple, presenting a potential opportunity for investors, though margin risks persist.

finance.yahoo.com2 min
OCT 25
Low

LIVE: Israeli forces turn Palestinian homes into military posts in Hebron

Israeli forces have seized Palestinian homes in Hebron for military use, displacing residents, following an attack that killed two Israeli soldiers. Opposition leader Gadi Eisenkot criticized PM Netanyahu's plan to use cryptocurrencies to avoid sanctions, warning of economic risks. UK MP John McDonnell urged full sanctions on Israel over West Bank actions.

news.az3 min
What people build

Built for AI agents and trading bots.

01MCP

"Claude, what moved NVDA today?"

alphai_news_search → MCP

Try it
02REST API

"Send only high-relevance earnings news for my watchlist."

/api/news/?category=earnings · min_relevance=7

Try it
03REST API

"Build a Telegram bot for market-moving news in 10 minutes."

/api/news/trending/ + your bot framework

Try it
04MCP

"Any insider buying in my watchlist this week?"

alphai_insider_news → MCP · /api/news/insider/

Try it
05MCP

"Feed my agent relevance-scored financial news via MCP."

OAuth 2.1 · News & watchlist tools · Streamable HTTP

Try it
Built for developers

Stock news API with sentiment and relevance scores

The same scored news feed that powers AlphAI is available as a REST API, and as an MCP server for Claude Desktop, Cursor, and any other agent host. Articles arrive enriched and linked to tickers in real time.

  • Real-time + historical news
  • Per-ticker filters and search
  • Relevance-scored 1–10
  • Free tier + paid scale
Stock news API documentationFinancial news MCP server

Dropping it into an existing stack? The Python and n8n quick starts are copy-paste.

GET /api/news/
curl https://api.alphai.io/api/news/ \
  -H "Authorization: Bearer ${ALPHAI_API_KEY}" \
  -G -d "symbol=NVDA"

# → {
#   "results": [{
#     "original": {
#       "title": "Nvidia export curbs tighten...",
#       "summary": "The White House is expected to...",
#       "time_published": "2026-04-18T14:32:00Z"
#     },
#     "enrichment": {
#       "category": "macro",
#       "tickers": ["NVDA"],
#       "relevance_score": 9
#     }
#   }, ...],
#   "next_cursor": "MjAyNi0wNC0xOFQxNDozMjowMHw0Mg=="
# }
Pricing

Three plans. One feed.

Free reads the feed and probes the APIs. Paid plans drop the ads and scale up the rate.

See all plans

Free

$0forever
  • Unlimited articles on the website
  • REST + MCP: 20 / min · 100 / day each, 1 API key
  • Sponsored placements visible
Start for free

Basic

Early access
$2.99$7.99/month
  • No ads, unlimited watchlist
  • Daily digest of ticker alerts
  • REST API: 60 / min · 10,000 / day, 1 key
  • MCP server: 60 / min · 10,000 / day
Get started
Most popular

Pro

Early access
$9.99$24.99/month
  • Everything in Basic
  • REST API: 150 / min · 100,000 / day, 5 keys
  • MCP server: 150 / min · 100,000 / day + bulk
Get started

Subscribe now and keep this rate for as long as you stay subscribed. We will not raise it for you.

Don’t want to watch the feed? Follow a ticker and we’ll deliver a daily digest of everything that clears your relevance bar, so you don’t have to check back.

Set up alerts